8:00am - 6.00pm EST | 5:00am - 3:00pm PST

* Please note that the following agenda timings are Eastern Standard Time.  

For Pacific Standard Times, please download the full event guide here

Driving Efficacy & Targeting in Solid Tumors

8:10 am Opening address from chair

8:20 am Landscape Review of CD3 Bispecifics


• Understanding the preclinical, and active CD3 targeted modalities within bispecific distribution
• Looking at the evolving bispecific clinical landscape, and the key insights
• Reviewing the contrasting bispecific development in solid tumors and hematological indications
• An overview of the global distribution of primary developers
• New technologies and the future: CD3 and beyond

8:45 am Novel Approaches for T-Cell Engagement


• Explore TCR-like T-cell engagers
• Overcome on target off tumor toxicity
• Combination with co-stimulation

9:10 am Targeting Prostate Cancer with T-Cell Engager Immune Therapies


• AMG 212 as first evidence for activity of a bispecific T-cell engager (BiTE) in prostate cancer
• Interim clinical data of next-generation BiTE immune therapy AMG 160 in mCRPC patients
• PSMA, STEAP1 and DLL3 targets and T-cell engager molecules in prostate cancer

9:35 am Live Q&A – Ask our Speakers Your Burning Questions

9:45 am Engineering of APVO442, a bispecific molecule with high affinity tumor targeting and low affinity binding to CD3 to potentially improve efficacy in solid tumors

  • Peter Pavlik Director of Molecular Biology and Antibody Engineering , Aptevo Therapeutics


  • APVO442 molecule is based on a novel ADAPTIR-FLEX format and designed to overcome limitations of high affinity CD3 T cell engagers for solid tumor indications.
  • Our unique anti-CD3 binding domain was engineered for low affinity, high stability and tumor-dependent CD3 activation and low cytokine release profile.
  • APVO442 combines bivalent anti-PSMA binding with monovalent low affinity anti-CD3 tumor-dependent activation and delivers optimal activation and potency across a range of PSMA expressing tumor targets.

10:10 am Benchmarking T-cell -Redirecting Therapies for Cancer: Comparing Bispecifics & CAR T Cells


• Two competing platforms exist for redirecting T-cells to recognize and kill tumors: Bispecific antibodies and chimeric antigen receptor (CAR) T-cells
• We have developed pre-clinical in vitro and in vivo models to mechanistically compare these two technologies and will discuss our findings as well as the clinical implications

10:35 am Live Q&A – Ask our Speakers Your Burning Questions

  • David DiLillo Associate Director, Regeneron Pharmaceuticals
  • Peter Pavlik Director of Molecular Biology and Antibody Engineering , Aptevo Therapeutics

10:45 am Virtual Networking Break

11:00 am Multi-functional Natural Killer Cell Engagers


• The cancer innate immunity cycle
• What’s next: Natural Killer Cell Engagers, including first generation: NKCE3
• NKCE3 to NKCE4, new data from next generation technology
• The ANKETTM platform: antibody-based NK cell engager therapeutics

11:25 am Triclonics™ ENGAGE: Trispecific Antibody Platform for Tumor Specific T-Cell Engagers


• Identify targets for Triclonics antibodies
• Explore therapeutic opportunities of trispecific T-cell engagers
• Overcome T-cell engager toxicities

11:50 am Bispecific Anti-PD-1/PD-L1 Antibody CTX-8371 Promotes Immunological Synapse Formation & PD-1 Shedding With Superior Anti-Tumor Activity & Favorable Tolerability


• Unique mechanism of action
• Superior activity
• Pk and tolerability

12:15 pm Live Q&A – Ask our Speakers Your Burning Questions

12:30 pm The Promise of Vascularized Micro-Organs & Tumors for Drug Discovery


• Aracari Biosciences’ Vascularized Micro Organ (VMO™) and Vascularized Micro Tumor (VMT™) platforms contain 3D, fully human tissues that are supported by living, perfused blood vessels
• Molecules and/or immune cells are delivered through the vascularized system directly to these tissues
• Gene expression and drug responses in the VMO and VMT models closely align with in vivo dose response and gene expression data, whereas data from monolayer and spheroid cultures do not

12:45 pm Live Q&A – Ask our Speakers Your Burning Questions

12:50 pm Networking Lunch

1:20 pm Panel Discussion: Mitigation Against On-Target, Off Tumor


• Discuss methods to override on-target off-tumor toxicities
• What tumor-associated antigens (TAA) are being specifically targeted to mitigate against toxicity?
• What progress has there been in identifying these targets?
• How can this specificity be exploited to create a more potent mode-of-action to treat solid tumor indications and address challenges in terms of tumor-cell accessibility and immunosuppression within the tumor microenvironment?
• What are the critical clinical considerations to make when developing TAA targeting cell engagers?

Modulating the Immune System to Drive Efficacy – Co-Stimulatory Targets

2:05 pm 4-BB Agonism in Immuno-Oncology – Presenting Our Immunotherapy Approaches Using Tumor-Localized 4-1BB Engagement

  • Janet Peper Senior Scientist, Translational Science, Pieris Pharmaceuticals

2:30 pm CB307 Tri-Partite Humabody® Enhances T-Cells Through PSMA-Dependent CD137 (4-1BB) Agonism


• CB307 monovalently binds PSMA, CD137 and HSA, to promote tumourspecific T-cell enhancement
• Humabodies have superior tissue penetration relative to standard monoclonal antibodies
• A CB307 mouse surrogate promotes tumour infiltration of CD8+ T-cells in PBMC engrafted mouse models

2:55 pm Tumor-Targeted CD28 Costimulatory Bispecific Antibodies Enhance T-Cell Activation in Solid Tumors


• Antigen presenting cells typically provide T-cell costimulation by providing CD28 ligands during T-cell priming
• We hypothesized that additional CD28 signaling at the T-cell: tumor cell interface could be beneficial
• We designed B7H3 x CD28 and PDL1 x CD28 bispecific antibodies that conditionally costimulate CD28 only in the presence of their respective targets and TCR engagement, and show that they enhance activity of either anti-PD1 antibodies or TAA x CD3 T cell engagers

3:20 pm Live Q&A – Ask our Speakers Your Burning Questions

3:35 pm HBICETM-Based B7H4x4-1BB Bispecific Provides Tumor Specific 2nd Costimulatory Signal & Anti-Tumor Immune Response

  • Yiping Rong Head of Discovery Biology, Harbour Biomed


• HBICE is heavy chain only based bispecific immune cell engager platform. It offers versatile bispecific formats to accommodate different biology mechanism of actions, particularly for multivalent, multispecific and geometry sensitive designs for immune cell engager
• Fine-tuned B7H4x4-1BB bispecific format shows B7H4 dependent crosslinking and 4-1BB activation. The tumor specific 4-1BB activation presents potential excellent safety profile
• The 4-1BB mediate 2nd signal is critical for sustainable T-cell activation, proliferation and memory in low Effector:Target (E:T) cell ratio environment, such as solid tumors

4:00 pm APVO603: A distinct dual agonistic bispecific approach to facilitate anti-tumor activity and overcome limitations of monoclonal OX-40 and 4-1BB targeting

  • Hilario Ramos Senior Director of Immuno-Biology , Aptevo Therapeutics


  • APVO603 is a dual 4-1BB and OX40 targeting bispecific immune agonist built on Aptevo’s ADAPTIRTM platform and is designed for single agent activity or combination with additional IO or T cell engaging approaches.
  • The distinct bispecific engineering of APVO603 is designed to deliver cis and trans cellular interactions with the potential to enhance effector function and survival, and limit or reverse suppressive or exhausted phenotypes on recently activated CD4+ and CD8+ T and NK cells.
  • The unique design of APVO603 requires dual 4-1BB and OX40 crosslinking for activity and therefore alleviates on-target toxicities observed with single agent agonists.

4:10 pm Live Q&A – Ask our Speakers Your Burning Questions

4:20 pm Virtual Networking Break

Harnessing the Power of the Innate System for Cell Engagers

4:40 pm Affinity Maturation of B7-H6 Translates Into Enhanced NK Cell-Mediated Tumor Cell Lysis & Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement

  • Lukas Roth Senior Scientist, Protein Engineering and Antibody Technologies, Merck KGaA


• We optimized a ligand for NK cell activating receptor NKp30 by yeast surface display
• When reformatted into bispecific immunoligands using Fab arm derived from Cetuximab significant tumor cell killing could be obtained
• Affinity enhanced ligand displayed distinguished cytokine release profiles compared to therapeutic antibody Cetuximab

5:05 pm Bispecific Antibodies to Engage Vγ9Vδ2-T Cells for Cancer Immunotherapy


• Vγ9Vδ2-T cells constitute the largest γδ-T cell subset in human peripheral blood and are powerful anti-tumor immune effector cells
• Bispecific antibodies designed to engage Vγ9Vδ2-T cells and their use for cancer immunotherapy will be discussed

5:30 pm Combination Therapies with Innate Cell Engagers to Fight for Patients in Need

  • Joachim Koch Head of Translational Research & Innovation, Affimed GmbH


• Innate Cell Engagers (ICE® molecules) activate NK cells and macrophages, inducing ADCC and ADCP respectively, to kill tumor cells
• Combination of ICE® molecules with other I/O therapies has shown promising results, pre-clinically and clinically, and may represent new therapeutic options for patients in need
• Therapeutic combination approaches are biology driven and target-specific, and may include ICE® molecules in combination with NK cell products or PD-(L)1 checkpoint inhibitors or others

5:55 pm Live Q&A – Ask our Speakers Your Burning Questions

  • Lukas Roth Senior Scientist, Protein Engineering and Antibody Technologies, Merck KGaA
  • Hans van der Vliet CSO, Lava Therapeutics
  • Joachim Koch Head of Translational Research & Innovation, Affimed GmbH

6:10 pm Chair’s Closing Remarks

6:20 pm End of Conference Day One